Comparison of once-daily ebastine 20 mg, ebastine 10 mg, loratadine 10 mg, and placebo in the treatment of seasonal allergic rhinitis

Journal of Allergy and Clinical Immunology

Volumn 105, Issue 6 II, 2000, Pages 1101-1107

  Ratner, Paul H ^a,b   Lim, Janet C ^b   Georges, George C ^c  

^a Sylvana Research ^*

^b Sylvana Research   (United States)

^c SANOFI   (France)

Author keywords

Antihistamine; Ebastine; Loratadine; Seasonal allergic rhinitis

Indexed keywords

EBASTINE; HISTAMINE H1 RECEPTOR ANTAGONIST; LORATADINE;

ADOLESCENT; ADULT; ALLERGIC RHINITIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERANCE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; BUTYROPHENONES; CHILD; DOUBLE-BLIND METHOD; FEMALE; HISTAMINE H1 ANTAGONISTS; HUMANS; LORATADINE; MALE; MIDDLE AGED; PIPERIDINES; RHINITIS, ALLERGIC, SEASONAL;

EID: 0033945766     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1067/mai.2000.105525     Document Type: Article

References (19)

1. Blaiss MS. How to determine the cost-effectiveness of available allergic rhinitis treatments. Drug Benefit Trends 1998;10:32-6.
2. Gergen PJ, Turkeltaub PC, Kovar MG. The prevalence of allergic skin test reactivity to eight common aeroallergens in the US population: results from the second National Health and Nutrition Examination Survey. J Allergy Clin Immunol 1987;80:669-79.
3. Ross RN. The costs of allergic rhinitis. Am J Man Care 1996;2:285-90.
4. Stempel DA. Improving the value of care for allergic rhinitis. Drug Benefit Trends 1996;8:11-12, 15,51.
5. Davies RJ. Efficacy and tolerability comparison of ebastine 10 and 20mg with loratadine 10mg: a double-blind, randomised study in patients with perennial allergic rhinitis. Clin Drug Invest 1998;16:413-20.
6. Bousquet J, Gaudano EM, Palma Carlos AG, Staudinger H. A twelve-week, placebo-controlled study of the efficacy and safety of ebastine, 10mg and 20mg once-daily, in the treatment of perennial allergic rhinitis. Allergy 1999;54:562-8.
7. De Molina M, Cadahia A, Cano L, Sanz A. Efficacy and tolerability of ebastine at two dose levels in the treatment of seasonal allergic rhinitis. Drug Invest 1989; 1:40-6.
8. Storms WW. Clinical studies of the efficacy and tolerability of ebastine 10 or 20 mg once daily in the treatment of seasonal allergic rhinitis in the US. Drugs 1996;52(1 Suppl):20-5.
9. Gehanno P, Bremard-Oury C, Zeisser P. Comparison of ebastine to cetirizine in seasonal allergic rhinitis in adults. Ann Allergy Asthma Immunol 1996;76:507-12.
10. Luria X, Robert M, Antepara I, Basombre A, Castillo JA, Cisterö Am et al. A double-blind placebo controlled study of the efficacy and tolerability of ebastine and loratadine in seasonal allergic rhinitis patients [abstract]. Allergy 1995;50(26 Suppl):199.
11. Claritin brand of loratadine tablets. In: Physicians' desk reference. 53rd ed. Montvale (NJ): Medical Economics; 1999. p 2825-7.
12. Reinberg A, Gervais P, Levi F, Smolensky M, Del Cerro L, Ogolini CER. Circadian and circannual rhythms of allergie rhinitis: an epidemiologic study involving chronobiologic methods. J Allergy Clin Immunol 1988;81:51-62.
13. Smolensky MH, Reinberg A, Labrecque G. Twenty-four hour pattern in symptom intensity of viral and allergic rhinitis: treatment implications. J Allergy Clin Immunol 1995;95:1084-96.
14. Semprex-D capsules (acrivastine and pseudoephedrine HCl). In: Physician's desk reference. 53rd ed. Montvale (NJ): Medical Economics; 1999. p 1705-7.
15. Falliers CJ, Brandon ML, Buchman E, Connell JT, Dockhorn R, Leese PT, et al. Double-blind comparison of cetirizine and placebo in the treatment of seasonal rhinitis. Ann Allergy 1991;66:257-62.
16. Wiseman LR, Faulds D. Ebastine: a review of its pharmacological properties and clinical efficacy in the treatment of allergic disorders. Drugs 1996;51:260-77.
17. Vincent J, Sumner DJ, Reid JL. Ebastine: the effect of a new antihistamine on psychomotor performance and autonomic responses in healthy subjects. Br J Clin Pharmacol 1988;26:503-8.
18. Morganroth J, Brozovich FV, McDonald JT, Jacobs RA. Variability of the QT measurement in healthy men, with implications for selection of an abnormal QT value to predict drug toxicity and proarrhythmia. Am J Cardiol 1991;67:774-6.
19. Molnar J, Zhang F, Weiss J, Ehlert FA, Rosenthal JE. Diurnal pattern of QTc interval: how long is prolonged? Possible relation to circadian triggers of cardiovascular events. J Am Coll Cardiol 1996;27:76-83.